Business Wire

ESG-CLEAN-ENERGY

Share
ESG Clean Energy Signs Letter of Intent with Ethatec GmbH to Use Carbon-Free Power Generation for Ethanol Production

ESG Clean Energy, LLC, developers of net zero, distributed power generation and clean energy manufacturing solutions, announced today it has signed a letter of intent (LOI) with Ethatec GmbH for the use of ESG’s patented CO2-free power generation technology to power its production of ethanol.

Under the LOI, US-based ESG Clean Energy will provide its patented carbon-capture system to enable Ethatec GmbH to produce different products in a sustainable way while preventing tons of carbon dioxide from entering the atmosphere every year.

Ethatec uses a unique process using waste from bakeries and pizza factories (old bread, dough, and other starch-based foods). The method involves first crushing and mixing the raw waste with water before being fed into a hammer mill. The resulting liquid is then mixed with water and enzymes and heated in a multi-stage mashing process to saccharify the starch. It is then cooled and fed into fermentation tanks. Yeast is then added for alcoholic fermentation of the sugar and after 72 hours, the mixture is fed to a distillation system where ethanol is obtained. Ethatec can also produce and manufacture other products using this unique system, including biogas and nitrogen fertilizer.

In order to meet the growing power demand for their production process, significant amounts of energy are required to run the operation. By using the ESG Clean Energy carbon-capture power generation system, Ethatec will be able to use natural gas to power their manufacturing plants while achieving a net zero carbon footprint.

“We are excited to explore the new opportunities with Ethatec and see how our carbon-capture system can augment their unique manufacturing system,” said Lutz Deyerling, Vice President European Operations and Corporate Finance at ESG Clean Energy. “Combining their system with ESG’s carbon-capture technology would create one of the most environmentally friendly systems in the industry today.”

The ESG system is truly unique with its ability to create a Net Zero carbon outcome from a conventional, natural gas, internal combustion engine without loss of efficiency.

Exhaust gas contains a significant amount of water vapor and CO2 as naturally occurring byproducts of the combustion process. By separating those two elements, the ESG system can produce distilled water – and other commodities such as urea, methanol, and recycled plastics – while capturing close to 100% of the CO2.

As a result, Net Zero Carbon Footprint power production is achieved.

Besides electrical power generation, the ESG system can also be utilized in a number of different environments, including:

Plastics Recycling Operations – Can be made more affordable and safer for the environment by providing low-cost, CO2-free heat that is critical to its processing.

Nitrogen Removal – Can be done more efficiently and cleanly. Nitrogen can cause algae blooms in wastewater treatment plants and is a risk to human health, so its removal has become an emerging, worldwide concern.

Stranded Natural Gas Wells – Can be effectively converted from non-operating revenue producers to operating revenue producers by incorporating the ESG system into its production process.

Microgrids – Can be made more reliable in times of emergency with the distributed power abilities of ESG power generation when regional grids go down.

Data Centers – Can provide large data centers with clean low-cost energy in a relatively small package.

Crypto Mining Operations – Can meet the energy demands of crypto mining operations without emitting carbon dioxide into the atmosphere.

For more information about ESG Clean Energy, please visit www.ESGcleanEnergy.com .

About ESG Clean Energy, LLC

ESG Clean Energy, LLC (ESG) develops Net Zero Carbon Footprints and clean energy solutions for businesses and power providers using natural gas. The ESG system utilizes patented, off-the-shelf technology to efficiently produce electricity while capturing and converting 100% of the carbon dioxide and water vapor, which can be used in the production of various commodities, such as distilled water, ethanol, and urea. More information about ESG Clean Energy, its technology, and its current projects can be found at www.ESGcleanEnergy.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release

FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74

Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release

Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release

Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce

Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release

Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv

Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release

The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye